

Shili Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4757580/publications.pdf>

Version: 2024-02-01

34
papers

2,064
citations

361413

20
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

3869
citing authors

#	ARTICLE	IF	CITATIONS
1	Giant Magnetoelastic Effect Enabled Stretchable Sensor for Self-Powered Biomonitoring. ACS Nano, 2022, 16, 6013-6022.	14.6	59
2	Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	36
3	Positron Emission Tomography Tracer Design of Targeted Synthetic Peptides via ¹⁸ F-Sydnone Alkyne Cycloaddition. Bioconjugate Chemistry, 2021, 32, 2073-2082.	3.6	7
4	Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology, 2020, 27, 197-205.e6.	5.2	16
5	Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics, 2020, 10, 829-840.	10.0	21
6	Chronic IL-1 β -induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Scientific Reports, 2020, 10, 377.	3.3	65
7	Comparison of the Efficacy and Sensitivity of Alternative PET Reporter Gene/PET Reporter Probe Systems That Minimize Biological Variables. Methods in Molecular Biology, 2020, 2126, 177-190.	0.9	1
8	Hexokinase 2 Is Targetable for HK1-Negative, HK2-Positive Tumors from a Wide Variety of Tissues of Origin. Journal of Nuclear Medicine, 2019, 60, 212-217.	5.0	18
9	A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers. Cancer Research, 2019, 79, 5907-5914.	0.9	71
10	Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. Computational Biology and Chemistry, 2019, 80, 374-383.	2.3	7
11	Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics, 2019, 9, 2282-2298.	10.0	35
12	An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1 ⁺ HK2 ⁺ Multiple Myeloma. Cancer Research, 2019, 79, 2748-2760.	0.9	41
13	Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6842-6847.	7.1	40
14	Development and Application of FASA, a Model for Quantifying Fatty Acid Metabolism Using Stable Isotope Labeling. Cell Reports, 2018, 25, 2919-2934.e8.	6.4	13
15	A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers. Cancer & Metabolism, 2018, 6, 7.	5.0	25
16	Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nature Communications, 2016, 7, 11457.	12.8	386
17	Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. British Journal of Cancer, 2015, 113, 242-251.	6.4	27
18	Protein disulfide isomerase: a promising target for cancer therapy. Drug Discovery Today, 2014, 19, 222-240.	6.4	223

#	ARTICLE	IF	CITATIONS
19	A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 2020-2030.	2.1	11
20	Abstract 1812: XCE853: A novel PDI inhibitor that inhibits proliferation of human tumor cells in vitro, ex-vivo and in vivo. , 2014, , .		0
21	Synthesis and SAR studies of marine natural products marine amines A, B and their analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5135-5139.	2.2	8
22	gp130: a promising drug target for cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1303-1328.	3.4	59
23	Stabilization of MDA-7/IL-24 for colon cancer therapy. <i>Cancer Letters</i> , 2013, 335, 421-430.	7.2	36
24	Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 937-949.	4.1	95
25	Small Molecule Inhibitors of CXCR4. <i>Theranostics</i> , 2013, 3, 47-75.	10.0	230
26	Loss of Survivin in the Prostate Epithelium Impedes Carcinogenesis in a Mouse Model of Prostate Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e69484.	2.5	14
27	Abstract 5513: Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase (PDI) for ovarian cancer treatment.. , 2013, , .		0
28	Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16348-16353.	7.1	200
29	Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9492-9509.	6.4	46
30	Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6645-6668.	6.4	168
31	Small-Molecule Inhibitors of p53-MDM2 Interaction: the 2006-2010 Update. <i>Current Pharmaceutical Design</i> , 2011, 17, 536-559.	1.9	56
32	Abstract C148: SC144: The first orally active small molecule gp130 inhibitor for the treatment of ovarian cancer.. , 2011, , .		0
33	Biological evaluation of Paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. <i>Cancer Biology and Therapy</i> , 2010, 9, 192-203.	3.4	36
34	A chemical lipid modification of recombinant preS antigen to study the mechanism of HBV attachment to the host cell. <i>Journal of Biotechnology</i> , 2008, 137, 8-13.	3.8	0